Home / Business News (page 2)

Business News

Personal Genome Diagnostics and PathGroup Partner to Accelerate the Availability of Comprehensive Genomic Profiling with TMB

BALTIMORE–(BUSINESS WIRE)–Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, and PathGroup, a premier provider of anatomic, clinical and molecular laboratory services, announced today that they have entered into a co-development agreement for the PGDx elio™ tissue complete assay. This collaboration brings together PGDx’s scientific, development and regulatory expertise …

Read More »

Lilly to Pay $8 Billion to Acquire Loxo Oncology

Eli Lilly and Company (NYSE: LLY) and Loxo Oncology, Inc. (NASDAQ: LOXO) today announced a definitive agreement for Lilly to acquire Loxo Oncology for $235.00 per share in cash, or approximately $8.0 billion. Loxo Oncology is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers. The acquisition would be the …

Read More »

Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs

PARIS and TARRYTOWN, NY – January 7, 2019 – Sanofi (EURONEXT: SAN, NASDAQ: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have restructured their global Immuno-oncology Discovery and Development Agreement for new immuno-oncology cancer treatments. The 2015 Agreement was scheduled to end in approximately mid-2020, and this revision provides for ongoing collaborative development of two clinical-stage …

Read More »

QIAGEN Acquires N-of-One, Expanding Its Clinical Bioinformatics Capabilities in Molecular Oncology Decision Support

Redwood City, California, and Hilden, Germany, January 7, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today it has entered into an agreement to acquire N-of-One, Inc., a privately-held U.S. molecular decision support company and pioneer in clinical interpretation services for complex genomic data. The addition of N-of-One …

Read More »

Gilead and Yuhan Enter Collaboration and License Agreement to Develop Treatments for Advanced Fibrosis Due to Nonalcoholic Steatohepatitis

FOSTER CITY, Calif. & SEOUL, Korea–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) and Yuhan Corporation (000100.KS; Yuhan) today announced that the companies have entered into a licensing and collaboration agreement to co-develop novel therapeutic candidates for the treatment of patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH). Under the agreement, …

Read More »

Adaptive Biotechnologies and Genentech Enter Worldwide Collaboration and License Agreement to Develop Personalized Cellular Therapies for Treatment of Cancer

SEATTLE–(BUSINESS WIRE)–Adaptive Biotechnologies, an immune-driven medicine company, today announced that it will enter into a worldwide collaboration and license agreement with Genentech, a member of the Roche Group, to develop, manufacture and commercialize novel neoantigen directed T-cell therapies for the treatment of a broad range of cancers. The collaboration will …

Read More »

X-Chem and Vertex Expand Existing Partnership Focused on the Discovery and Development of Therapies for Severe, Genetic Diseases

WALTHAM, Mass.–(BUSINESS WIRE)–X-Chem, Inc., a privately held biotechnology company focused on applying its industry-leading DNA-encoded (DEX™) drug discovery engine to the generation of novel small molecule therapeutics, today announced the expansion of its collaboration with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Under the terms of the expanded agreement, X-Chem will apply …

Read More »

C4 Therapeutics Announces Transformation of Strategic Collaboration to Discover and Develop Degrader-Based Medicines with Roche

WATERTOWN, Mass.–(BUSINESS WIRE)–C4 Therapeutics (C4T) announced the transformation of its ongoing research and development partnership with Roche focusing on new cancer treatments based on C4T’s targeted protein degradation technology. “We are excited to see our partnership with Roche evolve and further accelerate our efforts to bring degrader-based medicines into the clinic,” …

Read More »

Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets

CAMBRIDGE, Mass. and WALTHAM, Mass., Jan. 04, 2019 (GLOBE NEWSWIRE) — Biogen Inc (Nasdaq: BIIB) and Skyhawk Therapeutics, Inc. (Skyhawk) today announced a strategic collaboration in which the companies will leverage Skyhawk’s SkySTAR™ technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases. Biogen will have the …

Read More »

Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target From Research Collaboration with Dicerna

INGELHEIM, Germany & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Boehringer Ingelheim and Dicerna Pharmaceuticals (NASDAQ: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Boehringer Ingelheim has exercised an option to receive exclusive rights to a second hepatic disease target emerging from its research collaboration and license agreement with Dicerna. The collaboration, established …

Read More »